- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
White paper details exclusive PureNano Continuous Crystallizer capabilities and potentially breakthrough results
As leading pharmaceutical companies continue to explore the benefits of continuous manufacturing and bottom-up nanoparticle creation, Microfluidics (OTCBB:MFLU) has rebranded its innovative MRT nanoparticle creation technology as the PureNano™ platform, featuring the PureNano Continuous Crystallizer. PureNano combines a unique machine with expert process development to achieve smaller and more consistent particle sizes than previously possible for many applications, especially within the pharmaceutical and energy industries.
The PureNano Continuous Crystallizer provides research teams with new tools and methods to create stable inhalable formulations, improve the bioavailability of antibiotics and target delivery of novel cancer treatments, among other possibilities. Additional applications of PureNano include multi-phase chemical reactions and process intensification.
A new white paper detailing the technology and featuring a pharmaceutical case study can be found online at www.microfluidicscorp.com/images/stories/PureNano_Crystallizer.pdf.
"PureNano is a milestone achievement of innovation for our company and represents a revolutionary and necessary step forward in the evolution of continuous crystallization," said Michael C. Ferrara, President and Chief Executive Officer of Microfluidics. "Beta units in the field are surpassing the expectations of our pharmaceutical customers, and we are excited to discover with them the technology's full potential. In addition, our PureNano partners - POWREX in Japan and Particle Sciences in the United States - continue to commit to PureNano as a differentiator and an important part of the future of nanomaterials processing."
PureNano/MRT is a globally-patent-pending technology with active filings and applications in Australia, Canada, China, Europe, India, Israel, Japan and the United States.
"Pharmaceutical companies are seeking solutions for continuous crystallization using high shear, and PureNano fits this trend," said Mimi Panagiotou, Ph.D., Microfluidics Chief Technology Officer and co-creator of the technology. "As a platform technology, PureNano opens new avenues for improving drug bioavailability, suspension stability and actives delivery for potential breakthrough applications."
To schedule a webinar with Dr. Panagiotou to discuss PureNano, or to submit a sample for Proof of Concept testing, visit www.microfluidicscorp.com.
Microfluidics (OTCBB: MFLU) is the exclusive producer of Microfluidizer® high shear fluid processors for uniform particle size reduction, robust cell disruption and bottom-up nanoparticle creation. Used primarily by pharmaceutical, biotechnology, chemical, cosmetic, nutraceutical/food and energy companies to research, develop and improve products with efficient processes, more than 3,000 Microfluidizer processors are installed at customer sites in 50 countries around the world. The innovative Microfluidics Technology Center, located at the company's headquarters outside Boston, Mass., is staffed by expert engineers with a wide range of nanotechnology and application experience for Proof of Concept and Process Development services.
By producing smaller particle sizes and a more narrow distribution than other technologies, with scaleup from lab to production guaranteed, Microfluidics enables companies to create tiny particles that achieve big results.
For more information, please click here
Barbara J. Rudolph
Rudolph Communications, LLC
Copyright © MicrofluidicsIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Take a trip through the brain July 30th, 2015
Nanometrics Announces Upcoming Investor Events July 28th, 2015